New and Emerging Biologics for Atopic Dermatitis

Baghoomian, Wenelia; Na, Chan Ho; Simpson, Eric L.

doi:10.1007/s40257-020-00515-1

Cited by 16 publications

(11 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminary results from the JADE Compare study suggest that Jakinibs may be superior to dupilumab in mitigating pruritus. More head‐to‐head studies comparing the efficacy of Jakinibs with dupilumab and other emerging biologics are needed 29,30 . Similarly, comparison of efficacy across Jakinibs is needed given the heterogeneity in molecular targets.…”

Section: Efficacy and Safetymentioning

confidence: 99%

“…More head-to-head studies comparing the efficacy of Jakinibs with dupilumab and other emerging biologics are needed. 29,30 Similarly, comparison of efficacy across Jakinibs is needed given the heterogeneity in molecular targets. Monitoring complete blood count, liver enzymes and lipids may be warranted for subsets of patients on oral Jakinibs based on clinical trials for other disease populations.…”

Section: Efficacy and Safetymentioning

confidence: 99%

See 1 more Smart Citation

Janus kinase inhibitors for atopic dermatitis: a promising treatment modality

et al. 2021

View full text Add to dashboard Cite

Summary Atopic dermatitis (AD) is chronic, pruritic, inflammatory skin disease that affects a significant portion of the population in industrialized nations. For nonresponders to conventional therapies, AD can significantly reduce sleep quality and quality of life. AD pathogenesis is multifactorial and involves multiple immune pathways, with recent evidence of T helper (Th)2, Th17 and Th22 axis attenuation in various AD endotypes and racial subtypes. Inhibition of the conserved Janus kinase (JAK) signalling pathway represents a promising therapeutic avenue to reduce the activation of multiple proinflammatory mediators involved in AD pathogenesis. JAK inhibitors exist in both oral and topical forms with variable specificity for the receptor tyrosine kinases JAK1, JAK2, JAK3 and tyrosine kinase 2. Oral formulations include abrocitinib, upadacitinib, baricitinib and gusacitinib, and are most appropriate for patients with moderate to severe AD. Emerging topical formulation in development include ruxolitinib and deglocitinib, which may be used in patients with localized AD and also adjunctively with systemic therapy in patients with more severe disease. With observed rapidity in itch relief and accompanying dramatic reduction in inflammatory lesion count, JAK inhibitors represent a promising new treatment to revolutionize the management of AD.

show abstract

Section: Efficacy and Safetymentioning

confidence: 99%

Section: Efficacy and Safetymentioning

confidence: 99%

Janus kinase inhibitors for atopic dermatitis: a promising treatment modality

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Tralokinumab is a human monoclonal antibody that specifically binds IL-13, preventing interaction with IL-13 receptor α1 (IL-13Rα1) and IL-13Rα2. 42 The safety and efficacy in AD patients are investigated in a phase IIb randomized, double blind, and placebo-controlled study. 43 The data demonstrate a fast improvement associated to a safety profile.…”

Section: Emergent Biological Drugsmentioning

confidence: 99%

New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding

Napolitano

Ruggiero

Fontanella

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease. Systemic treatment is usually mandatory in moderate‐to‐severe AD of the adult; these patients need to be informed about safe and effective management of AD also regarding the reproduction. Treating a pregnant woman with AD with systemic drugs may affect the unborn child. While effects of traditional systemic treatments for AD on female fertility, pregnancy, and breastfeeding are largely known, data about new emergent therapies for AD are still poor. Treating pregnant or lactating women with AD can be a challenge since no large clinical studies on its possible effects and side‐effects on conception, pregnancy, the unborn child and lactation are currently available for new AD treatments.

show abstract

“…AD is prone to relapse and is characterized by serious pruritus that impacts the quality of patients’ life [ 2 ]. The pathophysiology of AD is highly complex, which involves skin barrier dysfunction as well as abnormal type 2 inflammation or immune responses [ 3 ]. The standard medical treatment for AD is focused on the symptomatic relief through control of skin inflammation using topical corticosteroids and/or calcineurin inhibitors [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

IL-32 promotes the occurrence of atopic dermatitis by activating the JAK1/microRNA-155 axis

et al. 2022

View full text Add to dashboard Cite

Background This study aims to explore the mechanism of interleukin-32 (IL-32) affecting atopic dermatitis (AD) through the Janus-activated kinase-1 (JAK1)/microRNA-155 (miR-155) axis. Methods In this study, skin tissue samples and blood samples from normal subjects and patients with AD, human immortalized keratinocytes (HaCaT), and PA-induced mouse models of AD were selected for expression determination of IL-32, JAK1 and miR-155. The interaction among IL-32, JAK1 and miR-155 was identified with their roles in AD analyzed through loss- and gain-of-function assays. Results Elevated IL-32 was detected in AD tissues and blood samples and promoted the occurrence of AD. IL-32 upregulated JAK1 expression and phosphorylation of its downstream genes, thus activating the JAK signaling pathway. JAK1 promoted the expression of miR-155. IL-32/JAK1/miR-155 axis promoted inflammation in the AD skin reconstruction model. In vivo experiments further confirmed that IL-32 promoted AD development by activating the JAK1/miR-155 axis. Conclusion The present study underlined that IL-32 promoted the occurrence of AD by promoting JAK1 expression to upregulate miR-155 expression.

show abstract

New and Emerging Biologics for Atopic Dermatitis

Cited by 16 publications

References 62 publications

Janus kinase inhibitors for atopic dermatitis: a promising treatment modality

Janus kinase inhibitors for atopic dermatitis: a promising treatment modality

New emergent therapies for atopic dermatitis: A review of safety profile with respect to female fertility, pregnancy, and breastfeeding

IL-32 promotes the occurrence of atopic dermatitis by activating the JAK1/microRNA-155 axis

Contact Info

Product

Resources

About